1/2 Alcohol Associated Comorbidities and Microbiome Evaluation in HIV (ACME HIV)
1/2 HIV 酒精相关合并症和微生物组评估 (ACME HIV)
基本信息
- 批准号:9408280
- 负责人:
- 金额:$ 68.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAlcohol consumptionAlcoholic beverage heavy drinkerAlcoholsAnimalsAttenuatedBacteriaBiodiversityBioinformaticsBiological MarkersBloodBlood CirculationBrainButyratesCardiacCardiovascular DiseasesCohort AnalysisCollectionComorbidityDataEFRACEndotoxinsEnrollmentEvaluationEvaluation StudiesFundingFutureGastrointestinal tract structureGenomicsHIVHIV InfectionsHeart failureHeavy DrinkingHepaticHumanInflammationInflammatoryInterleukin-6InterventionIntestinesKnowledgeLeft Ventricular Ejection FractionMeasuresMembraneN-terminalOxidative StressParticipantPathway interactionsPatient Self-ReportPeptidesPermeabilityPharmacotherapyPrevotellaProbioticsProcessProductionRandomized Controlled TrialsRecruitment ActivityResourcesSample SizeSamplingSerumSiteSmokingStructureTestingTight JunctionsWorkalcohol measurementalcohol researchantiretroviral therapycardiovascular disorder riskgastrointestinalgut microbiomeheart disease riskheart functionimmune activationintestinal fatty acid binding proteinmicrobialmicrobiomemicrobiotamouse modelnew therapeutic targetpro-brain natriuretic peptide (1-76)reduced alcohol useresponsesextherapeutic targettherapy designtrimethyloxamine
项目摘要
HIV infected (HIV+) heavy drinkers are at risk for cardiovascular diseases (CVD) via myriad pathways. Heavy
alcohol use causes microbial translocation (MT) and inflammation. Additionally, alcohol-related changes in the
GI tract microbiome—termed dysbiosis—are central to this pro-inflammatory cascade and could serve as novel
therapeutic targets for reducing CVD risk among HIV+ heavy drinkers. Alcohol-associated dysbiosis is
characterized by a loss of gut bacterial biodiversity, a reduction in “beneficial” bacteria, and/or an expansion of
harmful or “pro-inflammatory” bacteria (e.g., those which produce trimethylamine N-oxide (TMAO), a
metabolite associated with increased CVD risk). While murine models show alcohol associated dysbiosis was
attenuated by probiotics even in the presence of continued alcohol consumption, there remains insufficient
knowledge to identify a therapeutic target in humans for two reasons: 1) most studies involve murine models;
and 2) scant human studies have small sample sizes with few HIV+ participants, and lack longitudinal
assessment of alcohol intake, inflammation, and CVD risk in relation to the GI microbiome. This application
addresses these gaps. We hypothesize that alcohol-associated dysbiosis will: (1) be greater in HIV+ very
heavy drinkers (AUDIT score≥20) vs. heavy drinkers (AUDIT<20); (2) increase biomarker levels of intestinal
permeability (e.g., intestinal fatty acid binding protein (IFABP), MT (e.g., endotoxin), inflammation (interleukin
6) and TMAO; and (3) increase serum biomarkers for and alter echocardiographic (Echo) measures of cardiac
function (N-terminal pro Brain Naturetic Peptide, NT pro-BNP, and left ventricular ejection fraction, LVEF,
respectively). To test these hypotheses, we will enroll 200 HIV+ participants from St. PETER HIV, a funded
RCT using pharmacotherapy to reduce alcohol use, smoking, inflammation, and CVD risk. This application,
Alcohol-associated CVD and Microbiome Evaluation Study (ACME HIV 1/2) leverages existing resources of St.
PETER HIV: participant recruitment, measures of alcohol consumption, biospecimen and biomarker collection;
expertise in alcohol, HIV, CVD, and microbial genomics. New data include: fecal samples to characterize the
GI microbiome, serum biomarkers, and echo measures. In response to RFA-AA-17-014, we will partner with
the Southern HIV & Alcohol Research Consortium (SHARC, ACME HIV 2/2) to corroborate our findings in
Aims 1 and 2 and to conduct combined cross-cohort analyses. We will complete the following SPECIFIC AIMS
among HIV+ heavy drinkers: AIM 1: To assess longitudinal qualitative and quantitative changes in the gut
microbiome (dysbiosis) associated with very heavy alcohol consumption. AIM 2: To determine the effect of
dysbiosis on intestinal permeability, MT, inflammation, and TMAO levels. AIM 3: To investigate the impact of
dysbiosis on biomarkers for and echo measures of cardiac structure and function. Completion of these aims
will lay groundwork for an intervention targeting alcohol-associated dysbiosis, which could profoundly reduce
inflammation and favorably impact CVD risk among HIV+ heavy drinkers.
感染艾滋病毒(HIV+)的酗酒者存在通过多种途径罹患心血管疾病(CVD)的风险。重的
饮酒会导致微生物移位 (MT) 和炎症。此外,与酒精相关的变化
胃肠道微生物组(称为生态失调)是这种促炎症级联反应的核心,可以作为新的
降低艾滋病毒+重度饮酒者的心血管疾病风险的治疗目标。酒精相关的生态失调是
其特征是肠道细菌生物多样性丧失、“有益”细菌减少和/或细菌数量增加
有害或“促炎”细菌(例如,产生三甲胺 N-氧化物 (TMAO) 的细菌,一种
与 CVD 风险增加相关的代谢物)。虽然小鼠模型显示酒精相关的生态失调
即使在持续饮酒的情况下,益生菌也会减弱,但仍然不足
确定人类治疗靶点的知识有两个原因:1)大多数研究涉及小鼠模型;
2)人类研究样本量小,HIV+参与者很少,并且缺乏纵向研究
评估与胃肠道微生物群相关的酒精摄入量、炎症和心血管疾病风险。这个应用程序
解决这些差距。我们假设酒精相关的生态失调将:(1)在 HIV+ 中更为严重
重度饮酒者(AUDIT 评分≥20)与重度饮酒者(AUDIT<20); (2)增加肠道生物标志物水平
渗透性(例如肠脂肪酸结合蛋白 (IFABP)、MT(例如内毒素)、炎症(白细胞介素
6) TMAO; (3) 增加血清生物标志物并改变心脏超声心动图 (Echo) 测量值
功能(N 端脑自然肽原、NT 脑钠肽原、左心室射血分数、LVEF、
分别)。为了检验这些假设,我们将招募 200 名来自 St. PETER HIV 的 HIV+ 参与者,St. PETER HIV 是一家受资助的机构。
使用药物疗法来降低饮酒、吸烟、炎症和心血管疾病风险的随机对照试验。这个应用程序,
酒精相关的 CVD 和微生物组评估研究 (ACME HIV 1/2) 利用圣路易斯的现有资源。
PETER HIV:参与者招募、饮酒量测量、生物样本和生物标志物收集;
酒精、艾滋病毒、心血管疾病和微生物基因组学方面的专业知识。新数据包括:粪便样本来表征
胃肠道微生物组、血清生物标志物和回声测量。为了响应 RFA-AA-17-014,我们将与
南方艾滋病毒和酒精研究联盟(SHARC,ACME HIV 2/2)证实了我们的研究结果
目标 1 和 2 并进行组合的跨队列分析。我们将完成以下具体目标
HIV+ 重度饮酒者:目标 1:评估肠道的纵向定性和定量变化
微生物组(生态失调)与大量饮酒有关。目标 2:确定效果
肠道通透性、MT、炎症和TMAO水平的菌群失调。目标 3:调查影响
心脏结构和功能的生物标志物和回波测量的生态失调。完成这些目标
将为针对酒精相关生态失调的干预措施奠定基础,这可能会大大减少
炎症并对 HIV+ 重度饮酒者的 CVD 风险产生有利影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHIRISH S BARVE其他文献
SHIRISH S BARVE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHIRISH S BARVE', 18)}}的其他基金
Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention
酒精滥用、肠道微生物失调和 PrEP 护理连续体:SBIRT 干预的应用和功效
- 批准号:
10701829 - 财政年份:2022
- 资助金额:
$ 68.42万 - 项目类别:
Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention
酒精滥用、肠道微生物失调和 PrEP 护理连续体:SBIRT 干预的应用和功效
- 批准号:
10542284 - 财政年份:2022
- 资助金额:
$ 68.42万 - 项目类别:
Microbiome, Metabolites, and Alcohol in HIV to Reduce CVD (Supplement)
HIV 中的微生物组、代谢物和酒精可减少 CVD(补充)
- 批准号:
10672807 - 财政年份:2021
- 资助金额:
$ 68.42万 - 项目类别:
Microbiome, Metabolites, and Alcohol in HIV to Reduce CVD (META HIV CVD)
HIV 中的微生物组、代谢物和酒精可减少 CVD(META HIV CVD)
- 批准号:
10685506 - 财政年份:2021
- 资助金额:
$ 68.42万 - 项目类别:
Microbiome, Metabolites, and Alcohol in HIV to Reduce CVD (Supplement)
HIV 中的微生物组、代谢物和酒精可减少 CVD(补充)
- 批准号:
10846342 - 财政年份:2021
- 资助金额:
$ 68.42万 - 项目类别:
Microbiome, Metabolites, and Alcohol in HIV to Reduce CVD (META HIV CVD)
HIV 中的微生物组、代谢物和酒精可减少 CVD(META HIV CVD)
- 批准号:
10304046 - 财政年份:2021
- 资助金额:
$ 68.42万 - 项目类别:
Role of Gut Microbial Dysbiosis and Aging on HIV-associated neurocognitive and brain dysfunction
肠道微生物失调和衰老对 HIV 相关神经认知和脑功能障碍的作用
- 批准号:
10410552 - 财政年份:2018
- 资助金额:
$ 68.42万 - 项目类别:
Role of Gut Microbial Dysbiosis and Aging on HIV-associated neurocognitive and brain dysfunction
肠道微生物失调和衰老对 HIV 相关神经认知和脑功能障碍的作用
- 批准号:
10242623 - 财政年份:2018
- 资助金额:
$ 68.42万 - 项目类别:
相似海外基金
Molecular mechanisms of carcinogenesis and symptoms associated with alcohol consumption
致癌的分子机制和饮酒相关症状
- 批准号:
23K05734 - 财政年份:2023
- 资助金额:
$ 68.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The investigation of chronic alcohol consumption enhanced aging colon in elder mice and the mechanism of suppressed on aging colon tissues by sesame lignans continuous intake
长期饮酒促进老年小鼠结肠衰老的研究及持续摄入芝麻木脂素抑制结肠组织衰老的机制
- 批准号:
23K10904 - 财政年份:2023
- 资助金额:
$ 68.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Internal Sources of Minority Stress and Alcohol Consumption
少数群体压力和饮酒的内部根源
- 批准号:
10742318 - 财政年份:2023
- 资助金额:
$ 68.42万 - 项目类别:
Characterizing the Relationship Between Alcohol Consumption and Neuron-Derived Exosomal MicroRNA Cargo in an Adolescent-Young Adult Twin Cohort
青少年双胞胎队列中酒精消耗与神经元衍生的外泌体 MicroRNA 货物之间关系的表征
- 批准号:
10452928 - 财政年份:2022
- 资助金额:
$ 68.42万 - 项目类别:
Endocrine regulation of alcohol consumption and fear learning
饮酒和恐惧学习的内分泌调节
- 批准号:
10483780 - 财政年份:2022
- 资助金额:
$ 68.42万 - 项目类别:
The impact of friends sharing different modalities of alcohol-related social media content on alcohol consumption: A longitudinal examination of changes in content shared by social networks over time
朋友分享不同形式的酒精相关社交媒体内容对饮酒的影响:对社交网络分享内容随时间变化的纵向研究
- 批准号:
10534428 - 财政年份:2022
- 资助金额:
$ 68.42万 - 项目类别:
Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods
大麻对酒精消费的影响:整合实验室和生态瞬时评估方法
- 批准号:
10339931 - 财政年份:2022
- 资助金额:
$ 68.42万 - 项目类别:
Chronic alcohol consumption results in elevated Autotaxin levels that suppress anti-tumor immunity
长期饮酒会导致自分泌运动因子水平升高,从而抑制抗肿瘤免疫力
- 批准号:
10370159 - 财政年份:2022
- 资助金额:
$ 68.42万 - 项目类别:
Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods
大麻对酒精消费的影响:整合实验室和生态瞬时评估方法
- 批准号:
10595096 - 财政年份:2022
- 资助金额:
$ 68.42万 - 项目类别:
Technology-based assessments and intervention to reduce alcohol consumption and improve HIV viral suppression in the Florida Cohort
基于技术的评估和干预,以减少佛罗里达队列的饮酒量并改善艾滋病病毒抑制
- 批准号:
10707386 - 财政年份:2022
- 资助金额:
$ 68.42万 - 项目类别: